Ex­clu­sive: FDA prob­ing death of Aduhelm pa­tient as Bio­gen's Alzheimer's drug con­tin­ues to stir con­tro­ver­sy

The FDA tells End­points News to­day that it’s aware of the death of a pa­tient tak­ing Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm (ad­u­canum­ab) and is “ac­tive­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER